Key result
Combinatorial RNA interference (coRNAi) strategies against multiple HCV genotypes aim to balance in vivo safety, efficiency, and specificity, promising to restrict viral escape mutants.
Combinatorial RNA interference strategies show promise in targeting multiple HCV genotypes while balancing safety and restricting viral escape mutants.
Roughly two decades after its discovery and cloning, hepatitis C virus (HCV)—a pathogen infecting up to 180 million people worldwide and capable of causing severe liver disease, including cirrhosis and hepatocellular carcinoma—remains a frustrating target for development of antiviral therapies. Two articles in this issue of Molecular Therapy now report combinatorial RNA interference (coRNAi) strategies1 against multiple HCV genotypes that aim to balance in vivo safety, efficiency, and specificity, and that promise to restrict viral escape mutants.
No takes yet. Share an insight, caveat, or question.
Dirk Grimm (2012) conducted an editorial in Hepatitis C virus (HCV) infection. Combinatorial RNA interference (coRNAi) strategies was evaluated. Combinatorial RNA interference (coRNAi) strategies against multiple HCV genotypes aim to balance in vivo safety, efficiency, and specificity, promising to restrict viral escape mutants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: